PBK and Miyoshi myopathy: For the first time, we have shown that an inhibitor of TOPK suppressed several MM‐supportive pathways and induced potent MM‐selective killing that synergized with a common component of current treatment regimens, making TOPK a suitable candidate for targeting in a clinical setting.